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Abstract
Background:  Epidemiologic and laboratory investigations suggest that aspirin and other
nonsteroidal anti-inflammatory drugs (NSAIDs) have chemopreventive effects against colon cancer
perhaps due at least in part to their activity against cyclooxygenase-2 (COX-2), the rate-limiting
enzyme of the prostaglandin cascade.
Methods: We conducted a case control study of colon cancer designed to compare effects of
selective and non-selective COX-2 inhibitors. A total of 326 incident colon cancer patients were
ascertained from the James Cancer Hospital, Columbus, Ohio, during 2003–2004 and compared
with 652 controls with no history of cancer and matched to the cases at a 2:1 ratio on age, race,
and county of residence. Data on the past and current use of prescription and over the counter
medications and colon cancer risk factors were ascertained using a standardized risk factor
questionnaire. Effects of COX-2 inhibiting agents were quantified by calculating odds ratios (OR)
and 95% confidence intervals.
Results: Results showed significant risk reductions for selective COX-2 inhibitors (OR = 0.31, 95%
CI = 0.16–0.57), regular aspirin (OR = 0.33, 95% CI = 0.20–0.56), and ibuprofen or naproxen (0.28,
95% CI = 0.15–0.54). Acetaminophen, a compound with negligible COX-2 activity and low dose
aspirin (81 mg) produced no significant change in the risk of colon cancer.
Conclusion:  These results suggest that both non-selective and selective COX-2 inhibitors
produce significant reductions in the risk of colon cancer, underscoring their strong potential for
colon cancer chemoprevention.
Background
Among American men and women, colon cancer is the
third most frequently diagnosed malignancy and third
leading cause of cancer death [1]. In the past two decades,
incidence and mortality rates for colon cancer have
declined by more than 20% in women and men [1,2].
While some authors attribute these downward trends to
early detection and more effective therapy [2], the exact
reasons are not yet fully understood. One factor that may
have contributed to these declines is the widespread
intake of aspirin, ibuprofen and other nonsteroidal anti-
inflammatory drugs (NSAIDs)[3]. Among 22 published
epidemiologic studies that focused on the association
between intake of NSAIDs and the risk of human colon
cancer, 20 reported statistically significant risk reductions.
Meta-analysis of these data suggests that regular NSAID
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intake (primarily aspirin) reduces the risk of colon cancer
by about 60% [4].
Two selective COX-2 inhibitors, celecoxib (Celebrex) and
rofecoxib (Vioxx), were approved for the treatment of
arthritis by the United States Food and Drug Administra-
tion (FDA) in 1999 [3]. Until the recall of Vioxx in Sep-
tember, 2004, these two compounds plus other selective
COX-2 inhibitors valdecoxib (Bextra) and meloxicam
(Mobic) were widely utilized in the United States for pain
relief and treatment of osteoarthritis and rheumatoid
arthritis [5,6]. The time period between approval of
celecoxib to the recall of rofecoxib provides an approxi-
mate six-year window for evaluation of exposure to these
compounds by a case control approach. The current case
control study was designed to test and compare the chem-
opreventive value of selective and nonselective COX-2
inhibitors against human colon cancer.
Methods
We studied 326 cases of invasive colon cancer with histo-
logical verification based upon review of the pathology
records, and 652 group-matched controls with no per-
sonal history of cancer and no current gastrointestinal dis-
ease. Cases were sequentially ascertained for interview at
the time of their diagnosis during 2003 through Septem-
ber, 2004 at The Arthur G. James Cancer Hospital and
Richard J. Solove Research Institute (CHRI), Columbus,
Ohio. There were no refusals to participate among cases.
The controls were ascertained from the mammography
unit and prostate screening services of the cancer hospital
during the same time period and frequency matched to
the cases at a rate of 2:1 by five-year age interval, race, and
place (county) of residence. We interviewed randomly
selected controls from these screening facilities through-
out the time frame of the study to achieve a 2:1 ratio by
gender, age, race and county of residence. Among men
and women approached and eligible for participation,
95% completed the questionnaire. The protocol was
approved by the Human Subjects Cancer Internal Review
Board of The Ohio State University Medical Center and
informed consent documentation was obtained for partic-
ipants.
Critical information on exposure to NSAIDs and other
factors were obtained utilizing a standardized risk factor
questionnaire. The questionnaires were administered in
person by trained medical personnel (who were blinded
as to the purpose of the study) prior to definitive surgery
or treatment for the cases and at the time of screening
mammography or screening for prostate cancer for con-
trols. The data variables collected consisted of demo-
graphic characteristics, height, weight, menstrual and
pregnancy history for women, family history of colon can-
cer, comprehensive information on cigarette smoking,
alcohol intake, pre-existing medical conditions (arthritis,
chronic headache, cardiovascular conditions including
hypertension, angina, ischemic attacks, stroke, and myo-
cardial infarction, lung disease, and diabetes mellitus),
and medication history including over the counter (OTC)
and prescription NSAIDs, and exogenous hormones.
Regarding selective COX-2 inhibitors and other NSAIDs,
the use pattern (frequency, dose, and duration), and the
type, (celecoxib, valdecoxib, rofecoxib, meloxicam, aspi-
rin, ibuprofen, naproxen, indomethacin) were recorded.
Data on the related analgesic, acetaminophen were col-
lected for comparison with selective COX-2 inhibitors and
other NSAIDs.
Case-control differences in means and frequencies were
checked for statistical significance by t-tests and chi square
tests, respectively. Effects of the selective COX-2 inhibitors
as a group were quantified by estimating odds ratios and
their 95% confidence intervals. Odds ratios were adjusted
for age and colon cancer risk factors (family history, body
mass, chronic smoking, and regular alcohol intake) by
logistic regression analysis [7,8]. Adjusted estimates were
obtained for specific types of compounds, e.g., aspirin,
ibuprofen or naproxen, selective COX-2 inhibitors
(rofecoxib and celecoxib), and acetaminophen. Estimates
for selective COX-2 inhibitors were also adjusted for prior
intake of other types of NSAIDs.
Results
Pertinent characteristics of the cases and controls are given
in Table 1. The cases exhibited higher frequencies of
hypertension (OR = 2.87, 95% CI = 2.10–3.92) family
history of colon cancer (OR = 1.58, 95% CI = 1.08–2.30)
and chronic cigarette smoking (OR = 2.07, 95% CI =
1.49–2.87). Cases and controls had similar distributions
of matching variables, age, gender, race and county of res-
idence as well as education, body mass and alcohol con-
sumption.
Table 2 shows the comparative frequencies of the medica-
tions under study with multivariate-adjusted odds ratios
and 95% confidence intervals. A significant reduction in
the risk of colon cancer was observed for daily intake of
selective COX-2 inhibitors for one year or more (Adjusted
OR = 0.31, 95% CI = 0.16–0.57). Joint use of COX-2
inhibitors with aspirin or other NSAIDs was reported by
9.4% of subjects; however, the odds ratio for COX-2
inhibitors was not appreciably changed with additional
adjustment for the prior intake of such compounds (OR =
0.40, 95% CI = 0.25–0.82). Estimates for smokers and
nonsmokers and subjects with and without hypertension
were also similar. When the data were stratified by gender,
the risk reduction for the selective COX-2 inhibitors was
stronger for women (OR = 0.20, 95% CI = 0.08–0.46)
than men (OR = 0.75, 95% CI = 0.29–2.20).BMC Cancer 2008, 8:237 http://www.biomedcentral.com/1471-2407/8/237
Page 3 of 6
(page number not for citation purposes)
Significant risk reductions were also observed for the
intake of one or more pills per week of regular aspirin (OR
= 0.33, 95% CI = 0.20–0.56), and ibuprofen or naproxen
(0.28, 95% CI = 0.15–0.54). Low dose (81 mg) aspirin
produced a risk reduction with marginal significance (OR
= 0.58, 95% CI = 0.35–1.20) whereas acetaminophen had
no effect on the relative risk of colon cancer. Aspirin was
used for cardioprotection by 9% of subjects taking 325 mg
tablets compared to 93% of subjects taking 81 mg tablets.
Table 1: Characteristics of colon cancer cases and controls.
Characteristic a Cases (N = 326) Controls (N = 652)
Gender
Female 45% 45%
Age (yrs)
<50 15% 11%
50–59 22 25
60–69 32 34
>65 31 30
Mean (SEM) 63.2 (0.7) 63.5 (0.6)
Race
Caucasian 90% 86%
Residence
Franklin County, Ohio 81% 83%
Adjacent Counties 18 15
Other 1 2
Education
< 12 yrs 12% 12%
12 yrs 53 55
> 12 yrs 35 33
Family History
Positive 20% 13% (p < 0.01)
Body Mass
BMI < 22 14% 12%
BMI 22–27 32 40
BMI > 27 55 48
Mean (SEM) 29.1 (0.5) 28.1 (0.3)
Smoking
(>10 Pack-years) 33% 22% (p < 0.01)
Alcohol Intake
None 47% 45%
1–2 drinks per week 36 35
> 2 drinks per week 17 20
Hypertension 47% 28% (p < 0.01)
a Family History: colon cancer among first or second degree relatives; Body Mass Index = weight (kg)/ht 2 (m).
Table 2: Odds ratios with 95% confidence intervals for colon cancer and selective cyclooxygenase-2 (COX-2) inhibitors, and over the 
counter nonsteroidal anti-inflammatory drugs (OTC NSAIDS).
Compound Number of Cases (%) Number of Controls (%) Multivariate ORd (95% CI)
None/Infrequent Usea 236 (72) 352 (54) 1.00
COX-2 Inhibitorsb 15 (5) 53 (8) 0.31 (0.16–0.57)
OTC NSAIDsc
Aspirin 22 (7) 88 (13) 0.33 (0.20–0.56)
Ibuprofen/Naproxen 13 (4) 68 (11) 0.28 (0.15–0.54)
Acetaminophen 12 (3) 22 (3) 0.81 (0.35–1.61)
Baby Aspirin 28 (9) 69 (11) 0.58 (0.35–1.02)
a No use of any NSAID or analgesic or infrequent use of no more than one pill per week for less than one year;
b COX-2 inhibitors include celecoxib, rofecoxib, valdecoxib, and meloxicam used daily for one year or more.
c Over the counter (OTC) NSAIDs/analgesics used at least once per week for more than one year.
d Multivariate odds ratios are adjusted for continuous variables (body mass) and categorical variables (hypertension, family history, smoking, and 
alcohol intake).BMC Cancer 2008, 8:237 http://www.biomedcentral.com/1471-2407/8/237
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Table 3 presents risk estimates for individual selective
COX-2 inhibitors (celecoxib and rofecoxib) plus dose-
response data for aspirin and ibuprofen. Daily use of
either 200 mg celecoxib or 25 mg rofecoxib for more than
one year produced similar risk reductions (65% and 68%,
respectively). The average duration of use was 3.6 years.
The trend data for OTC compounds suggests that 325 mg
aspirin or 200 mg ibuprofen produced significant risk
reductions when taken daily for 5 or more years.
Discussion
Our observation of a significant risk reduction in human
colon cancer due to intake of selective COX-2 inhibitors is
similar to that reported by Rahme et al. [9]. Standard daily
dosages of celecoxib (200 mg) or rofecoxib (25 mg) were
associated with a 69% reduction in colon cancer risk.
Notably, comparator NSAIDs with non-selective COX-2
activity (325 mg aspirin or 200 mg ibuprofen) also pro-
duced significant risk reductions of similar magnitude. In
contrast, the effect of low dose aspirin (81 mg) was only
marginally significant and acetaminophen, an analgesic
with little COX-2 activity, had no effect on the risk of
colon cancer.
Selective COX-2 inhibitors (celecoxib and rofecoxib) were
only recently approved for use in 1999, and rofecoxib
(Vioxx) was withdrawn from the marketplace in 2004 [3-
5]. Nevertheless, even in the short window of exposure to
these compounds, the selective COX-2 inhibitors pro-
duced significant reductions in the risk of colon cancer,
underscoring their strong potential for colon cancer che-
moprevention.
In general, NSAIDs inhibit cyclooxygenase which is the
key rate-limiting enzyme of prostaglandin biosynthesis
[10-12]. Molecular studies show that the inducible COX-
2 gene is over-expressed in human colon cancer and that
genetic expression of COX-2 in cancer cells is correlated
with mutagenesis, mitogenesis, angiogenesis, and deregu-
lation of apoptosis [13-15]. Over the counter NSAIDs
have consistently shown antitumor effects in animal mod-
els of carcinogenesis [16], and striking antitumor effects of
the specific COX-2 inhibitor, celecoxib, have been
observed against colon cancer [17]. Epidemiologic studies
and randomized clinical trials provide convincing evi-
dence that regular intake of aspirin and other NSAIDs not
only inhibit the development of colon cancer per se, but
also interrupt the evolution of preneoplastic lesions of the
colonic mucosa [18]. Furthermore, recent randomized
clinical trials of selective COX-2 inhibitors indicate that
celecoxib suppresses the development of colon adenomas
[19,20]. The current study coupled with existing clinical,
preclinical and molecular evidence suggest that aberrant
induction of COX-2 and up-regulation of the prostaglan-
din cascade play a significant role in colon carcinogenesis,
and that blockade of this process has strong potential for
intervention. It is noteworthy that NSAIDs also manifest
anticancer effects by mechanisms other than COX-2 inhi-
bition [21]. For example, celecoxib has been found to
have multiple COX-independent anticancer effects
including induction of apoptosis and inhibition of cell
cycle progression, angiogenesis, and metastasis [21,22].
Thus, it will be important to exploit not only COX-2
blockade but also COX-independent molecular targets of
these compounds [22].
Enthusiasm for the use of selective COX-2 blocking agents
in the chemoprevention of colon cancer and other malig-
nancies has been tempered by reports of adverse effects on
the cardiovascular system leading to the recall of the pop-
ular anti-arthritic compound, rofecoxib (Vioxx) [23-25],
and subsequently, the cardiovascular safety of all selective
COX-2 inhibitors has come under scrutiny [5]. However,
such studies involved supra-therapeutic dosages given
Table 3: Odds ratios for colon cancer by dose, frequency, and duration of exposure to celecoxib, rofecoxib, aspirin, and ibuprofen.
Compounda Dose Cases Controls Frequency of Use Multivariate ORb (95% CI)
N (%)
None 0 236 (72) 352 (54) None
Celecoxib 200 mg 8 (2) 27 (4) Daily 0.35 (0.18–0.93)
Rofecoxib 25 mg 7 (2) 26 (4) Daily 0.32 (0.12–0.83)
Aspirin 325 mg 5 (2) 14 (2) 1–2 weekly 0.87 (0.24–3.17)
4 (1) 8 (1) 3–6 weekly 0.73 (0.20–2.67)
13 (4) 66 (10) Daily 0.22 (0.12–0.41)
trend (p < 0.05)
Ibuprofen 200 mg 7 (2) 17 (3) 1–2 weekly 0.67 (0.26–1.69)
2 (1) 12 (2) 3–6 weekly 0.18 (0.02–1.50)
4 (1) 39 (6) Daily 0.19 (0.07–0.49)
trend (p < 0.01)
a Minimum duration of exposure: one year for celecoxib or rofecoxib, 5 years for aspirin or ibuprofen.
b Multivariate odds ratios are adjusted for continuous variables (body mass) and categorical variables (hypertension, family history, smoking, and 
alcohol intake).BMC Cancer 2008, 8:237 http://www.biomedcentral.com/1471-2407/8/237
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over long periods of time without consideration of body
size or individual differences in metabolism [26]. Never-
theless, not all studies reflect changes in cardiovascular
risk with exposure to COX-2 inhibitors [27,28] and
recently a large meta-analysis of existing randomized clin-
ical trials found no risk increase at any dose level of
celecoxib [29]. Further studies will be required to deter-
mine the appropriate dose, frequency of intake, duration,
side effects and cost effectiveness of selective and nonse-
lective COX-2 inhibitors in the chemoprevention of can-
cer.
Conclusion
We observed a significant reduction in the risk of human
colon cancer due to intake of both selective and nonselec-
tive COX-2 inhibitors. Chemopreventive effects against
colon cancer were associated with recommended daily
doses of celecoxib (median dose = 200 mg) or rofecoxib
(median dose = 25 mg) for an average duration of 3.6
years. Notably, the regular intake of over the counter
NSAIDs such as aspirin and ibuprofen produced risk
reductions in colon cancer similar in magnitude to the
selective COX-2 inhibitors.
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